Royalty Pharma
RPRX
336 hedge funds and large institutions have $11.8B invested in Royalty Pharma in 2022 Q4 according to their latest regulatory filings, with 61 funds opening new positions, 137 increasing their positions, 100 reducing their positions, and 36 closing their positions.
688% more call options, than puts
Call options by funds: $44.5M | Put options by funds: $5.65M
69% more first-time investments, than exits
New positions opened: 61 | Existing positions closed: 36
37% more repeat investments, than reductions
Existing positions increased: 137 | Existing positions reduced: 100
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
5% more funds holding
Funds holding: 319 → 336 (+17)
2% less capital invested
Capital invested by funds: $12.1B → $11.8B (-$275M)
1.25% less ownership
Funds ownership: 69.13% → 67.87% (-1.3%)
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$48.1M |
| 2 |
BlackRock
New York
|
+$47.7M |
| 3 |
SVCF
Silicon Valley Community Foundation
Mountain View,
California
|
+$43.1M |
| 4 |
Millennium Management
New York
|
+$38.5M |
| 5 |
Renaissance Technologies
New York
|
+$36.3M |
Top Sellers
| 1 |
SGA
Siguler Guff Advisers
New York
|
-$141M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$122M |
| 3 |
Capital International Investors
Los Angeles,
California
|
-$48.7M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$48.6M |
| 5 |
Morgan Stanley
New York
|
-$39.2M |
RPRX Hedge Fund Activity: Q4 2022 in Review
336 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q4 2022, worth a combined $11.8B — down 2.3% from $12.1B a quarter earlier.
Buyers outnumbered sellers: 61 funds opened new RPRX positions and 36 closed out — a net gain of 25 holders — while 137 added to existing stakes and 100 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $48.1M. The largest seller was Siguler Guff Advisers, cutting an estimated $141M.
- 336 institutional investors held Royalty Pharma (RPRX) as of Q4 2022, up from 319 in Q3 2022.
- Funds reported $11.8B of Royalty Pharma stock for Q4 2022, down 2.3% quarter-over-quarter.
- 61 funds opened new Royalty Pharma positions in Q4 2022 and 36 closed out, a net change of +25 holders.
- The largest Royalty Pharma buyer in Q4 2022 was Fidelity Investments, an estimated $48.1M added.
- The largest Royalty Pharma seller in Q4 2022 was Siguler Guff Advisers, an estimated $141M sold.
Based on aggregated 13F filings for Q4 2022.